Pelvic angioembolization only way to reduce mortality in Hemodynamically Unstable Pelvic Fractures: JAMA

Written By :  Aditi
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2022-12-04 14:30 GMT   |   Update On 2022-12-04 14:30 GMT

United States: A recent JAMA study has concluded that One in Three Patients with Unstable Pelvic Fractures Die, despite the availability of advanced haemorrhage control interventions.

The study also highlighted that only Pelvic Angioembolization (AE) could reduce mortality in such cases.

It is important to consider that treating hemodynamically unstable pelvic fractures is very challenging. The interventions used are either alone or in combination. The data remains insufficient on the question,

After a severe pelvic fracture, What is the association between an intervention (haemorrhage control) and outcomes?

The current question here is,

What is the current variation in nationwide practices for managing pelvic fracture-related haemorrhage?

With this objective, a team of researchers conducted a study to add data to this perspective. The lead researcher was Dr Anand et al. from the College of Medicine from the Division of Trauma, Critical Care, Burns, and Emergency Surgery at the University of Arizona.

The key points of the study are:

  • The primary outcomes measured were the 24-hour, emergency department, and in-hospital mortality rates.
  • The major in-hospital complications were the secondary outcomes measured.
  • The study identified a total of 1396 patients.
  • The Mean age of the patient was 47 years.
  •  70% of the study participants were male.
  • The mean systolic blood pressure (lowest) was 71 mm Hg.
  • The median Injury Severity Score was 24.
  • The 24-hour mortality was 15.5% ( 217 patients).
  • The in-hospital mortality was 36 % (501 patients).
  • The ED mortality was 0.7 % (10 patients).
  • The complication rate of 41 % (574 patients) was recorded.
  • The most common intervention was Pelvic AE, with 774 patients constituting 55%.
  • After pelvic AE, preperitoneal pelvic packing (PP), including 659 patients constituting 47% and resuscitative endovascular balloon occlusion of the aorta (REBOA) zone 3, including 126 patients constituting 9%, were the commonly followed intervention.
  •  One thousand two hundred thirty-six patients, nearly 89%, had one intervention.
  • Of one hundred fifty-seven patients, 11% had two interventions.
  •  In three patients, 0.2% had three interventions.
  • There was a reduction in mortality in only pelvic AE on regression analyses, with an odds ratio [OR] of 0.62. The P value was < .001.
  •  There were increased odds of complications associated with Preperitoneal PP with an OR of 1.39, a 95% Confidence Interval and a P value of 0.01.
  • An increasing number of interventions were tied to increased 24-hour transfusions with β = +5.4; 95% CI, P < .001 and mortality with OR of 1.57 and P = .03, but not with complications.

The researchers said we found that more than 1 in 3 patients died of pelvic fractures. There were those patients requiring early transfusions and invasive haemorrhage control interventions. These patients died even after the availability of various advanced haemorrhage control interventions.

We conclude that only pelvic AE reduced mortality alone.

Our study's findings underscore the algorithm's need to standardize care and improve outcomes in these cases.

Further reading:

Anand T, El-Qawaqzeh K, Nelson A, et al. Association Between Hemorrhage Control Interventions and Mortality in US Trauma Patients With Hemodynamically Unstable Pelvic Fractures. JAMA Surg. Published online November 30, 2022. doi:10.1001/jamasurg.2022.5772

Tags:    
Article Source : JAMA Surgery

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News